Protokinetix Inc
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications comprising targeted health care solutions, as well as AAGPs are used for applications in ophthalmology, dermatology, transplants, and biomanufa… Read more
Protokinetix Inc (PKTX) - Net Assets
Latest net assets as of September 2025: $250.43K USD
Based on the latest financial reports, Protokinetix Inc (PKTX) has net assets worth $250.43K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($477.62K) and total liabilities ($227.20K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $250.43K |
| % of Total Assets | 52.43% |
| Annual Growth Rate | 19.29% |
| 5-Year Change | -19.36% |
| 10-Year Change | -15.4% |
| Growth Volatility | 110.2 |
Protokinetix Inc - Net Assets Trend (2000–2024)
This chart illustrates how Protokinetix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Protokinetix Inc (2000–2024)
The table below shows the annual net assets of Protokinetix Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $342.09K | -21.51% |
| 2023-12-31 | $435.86K | +3.45% |
| 2022-12-31 | $421.34K | +19.37% |
| 2021-12-31 | $352.97K | -16.80% |
| 2020-12-31 | $424.22K | -24.30% |
| 2019-12-31 | $560.39K | +127.83% |
| 2018-12-31 | $245.97K | -34.15% |
| 2017-12-31 | $373.54K | -24.81% |
| 2016-12-31 | $496.80K | +22.86% |
| 2015-12-31 | $404.36K | +194.41% |
| 2014-12-31 | $-428.33K | +30.71% |
| 2013-12-31 | $-618.15K | -34.28% |
| 2011-12-31 | $-460.36K | +1.72% |
| 2010-12-31 | $-468.42K | -88.19% |
| 2009-12-31 | $-248.91K | -80.86% |
| 2008-12-31 | $-137.63K | +47.28% |
| 2007-12-31 | $-261.05K | -231.02% |
| 2006-12-31 | $199.25K | -92.69% |
| 2005-12-31 | $2.72 Million | -6.45% |
| 2004-12-31 | $2.91 Million | +30.25% |
| 2003-12-31 | $2.24 Million | +19431.52% |
| 2002-12-31 | $-11.56K | -332.93% |
| 2000-12-31 | $4.96K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Protokinetix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4822811100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.99K | 0.58% |
| Other Components | $48.57 Million | 14197.51% |
| Total Equity | $342.09K | 100.00% |
Protokinetix Inc Competitors by Market Cap
The table below lists competitors of Protokinetix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Conifex Timber Inc
PINK:CFXTF
|
$2.04 Million |
|
Cape Range Ltd
AU:CAG
|
$2.04 Million |
|
Birddog Technology Ltd
AU:BDT
|
$2.04 Million |
|
Kobexindo Tractors Tbk
JK:KOBX
|
$2.04 Million |
|
GETS Global Bhd
KLSE:5079
|
$2.04 Million |
|
TAKE-TWO INTERACT
BE:TKE
|
$2.03 Million |
|
AS Latvijas balzams
MU:UM9
|
$2.03 Million |
|
Zwahlen et Mayr SA
SW:ZWM
|
$2.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Protokinetix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 435,861 to 342,090, a change of -93,771 (-21.5%).
- Net loss of 364,000 reduced equity.
- New share issuances of 256,000 increased equity.
- Other factors increased equity by 14,229.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-364.00K | -106.4% |
| Share Issuances | $256.00K | +74.83% |
| Other Changes | $14.23K | +4.16% |
| Total Change | $- | -21.51% |
Book Value vs Market Value Analysis
This analysis compares Protokinetix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 63.73x to 12.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.00 | $0.01 | x |
| 2002-12-31 | $0.00 | $0.01 | x |
| 2003-12-31 | $0.08 | $0.01 | x |
| 2004-12-31 | $0.10 | $0.01 | x |
| 2005-12-31 | $0.07 | $0.01 | x |
| 2006-12-31 | $0.00 | $0.01 | x |
| 2007-12-31 | $-0.01 | $0.01 | x |
| 2008-12-31 | $0.00 | $0.01 | x |
| 2009-12-31 | $0.00 | $0.01 | x |
| 2010-12-31 | $-0.01 | $0.01 | x |
| 2011-12-31 | $0.00 | $0.01 | x |
| 2013-12-31 | $0.00 | $0.01 | x |
| 2014-12-31 | $0.00 | $0.01 | x |
| 2015-12-31 | $0.00 | $0.01 | x |
| 2016-12-31 | $0.00 | $0.01 | x |
| 2017-12-31 | $0.00 | $0.01 | x |
| 2018-12-31 | $0.00 | $0.01 | x |
| 2019-12-31 | $0.00 | $0.01 | x |
| 2020-12-31 | $0.00 | $0.01 | x |
| 2021-12-31 | $0.00 | $0.01 | x |
| 2022-12-31 | $0.00 | $0.01 | x |
| 2023-12-31 | $0.00 | $0.01 | x |
| 2024-12-31 | $0.00 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Protokinetix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.36x
- Recent ROE (-106.40%) is above the historical average (-295.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -0.70% | 0.00% | 0.00x | 1.04x | $-531.50 |
| 2002 | 0.00% | -11998.39% | 0.21x | 0.00x | $-13.72K |
| 2003 | -68.39% | 0.00% | 0.00x | 1.07x | $-1.75 Million |
| 2004 | -185.03% | 0.00% | 0.00x | 1.26x | $-5.68 Million |
| 2005 | -177.19% | -241350.00% | 0.00x | 1.18x | $-5.10 Million |
| 2006 | -987.71% | -98400.00% | 0.00x | 3.08x | $-1.99 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.70 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.54 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.25 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.34 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.19 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-387.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-125.17K |
| 2015 | -310.31% | 0.00% | 0.00x | 1.11x | $-1.30 Million |
| 2016 | -306.89% | 0.00% | 0.00x | 1.09x | $-1.57 Million |
| 2017 | -405.22% | 0.00% | 0.00x | 1.39x | $-1.55 Million |
| 2018 | -494.52% | 0.00% | 0.00x | 1.32x | $-1.24 Million |
| 2019 | -749.11% | 0.00% | 0.00x | 1.05x | $-4.25 Million |
| 2020 | -1801.89% | 0.00% | 0.00x | 1.11x | $-7.69 Million |
| 2021 | -659.84% | 0.00% | 0.00x | 1.26x | $-2.36 Million |
| 2022 | -452.60% | 0.00% | 0.00x | 1.10x | $-1.95 Million |
| 2023 | -95.21% | 0.00% | 0.00x | 1.10x | $-458.59K |
| 2024 | -106.40% | 0.00% | 0.00x | 1.36x | $-398.21K |
Industry Comparison
This section compares Protokinetix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Protokinetix Inc (PKTX) | $250.43K | -0.70% | 0.91x | $2.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |